<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02692170</url>
  </required_header>
  <id_info>
    <org_study_id>CVI-HBV-001-CT1201</org_study_id>
    <nct_id>NCT02692170</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine</brief_title>
  <official_title>A Single Center, Randomized, Double Blinded PhaseI/IIa Exploratory Study to Evaluate Reactogenicity, Safety, Immunogenicity and Dose Response of a New Hepatitis B Vaccine in Human Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHA Vaccine Institute Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHA Vaccine Institute Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, randomized, double blinded phase I/IIa exploratory study to evaluate&#xD;
      reactogenicity, safety, immunogenicity and dose-response of a new hepatitis B vaccine in&#xD;
      human adult&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Objectives: To explore the most effective dose of the third generation Hepatitis B&#xD;
           vaccine through the evaluation of reactogenicity, safety, and immunogenicity.&#xD;
&#xD;
        -  Subjects: Adults having anti-HBs antibody titers less than 10 mIU/mL after 3 previous&#xD;
           injections of the conventional Hepatitis B vaccine.&#xD;
&#xD;
        -  Study hypothesis: The third generation Hepatitis B vaccine, containing preS antigens in&#xD;
           addition to S antigen, has an ability to elicit faster protection and higher antibody&#xD;
           titers than the second generation Hepatitis B vaccine in the subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and reactogenicity (including incidence of adverse events and expected adverse reactions for vaccine treatment) measured for 7 days after each vaccination</measure>
    <time_frame>7 days after each vaccination</time_frame>
    <description>Occurrence of severe local and/or systemic reactogenicity signs and symptoms measured for 7 days after each vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate</measure>
    <time_frame>4 weeks after vaccination</time_frame>
    <description>Seroprotection (&gt; 10 mIU/mL of anti-HBs) rate measured 4 weeks after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers to HBsAg</measure>
    <time_frame>4 weeks after vaccination</time_frame>
    <description>Geometric mean titer (GMT, mIU/mL) measured 4 weeks after vaccination</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CVI-HBV-001 (5 μg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV surface antigen 5 μg/dose&#xD;
Intramuscular injection at 0, 1, 6th month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVI-HBV-001 (10 μg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV surface antigen 10 μg/dose&#xD;
Intramuscular injection at 0, 1, 6th month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVI-HBV-001 (20 μg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV surface antigen 20 μg/dose&#xD;
Intramuscular injection at 0, 1, 6th month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVI-HBV-001 (40 μg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV surface antigen 40 μg/dose&#xD;
Intramuscular injection at 0, 1, 6th month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Hepatitis B vaccine (20 μg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HBV surface antigen 20 μg/dose&#xD;
Intramuscular injection at 0, 1, 6th month</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CVI-HBV-001</intervention_name>
    <description>Investigational product: CVI-HBV-001&#xD;
Dose: 5, 10, 20 or 40ug&#xD;
Frequency: 3 times&#xD;
Vaccination schedule: at 0, 1, 6 months&#xD;
Administration route: Intramuscular injection</description>
    <arm_group_label>CVI-HBV-001 (10 μg)</arm_group_label>
    <arm_group_label>CVI-HBV-001 (20 μg)</arm_group_label>
    <arm_group_label>CVI-HBV-001 (40 μg)</arm_group_label>
    <arm_group_label>CVI-HBV-001 (5 μg)</arm_group_label>
    <arm_group_label>Conventional Hepatitis B vaccine (20 μg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conventional Hepatitis B vaccine (20 μg)</intervention_name>
    <description>Active comparator: Conventional Hepatitis B vaccine (20 μg)&#xD;
Dose: 20ug&#xD;
Frequency: 3 times&#xD;
Vaccination schedule: at 0, 1, 6 months&#xD;
Administration route: Intramuscular injection</description>
    <arm_group_label>CVI-HBV-001 (10 μg)</arm_group_label>
    <arm_group_label>CVI-HBV-001 (20 μg)</arm_group_label>
    <arm_group_label>CVI-HBV-001 (40 μg)</arm_group_label>
    <arm_group_label>CVI-HBV-001 (5 μg)</arm_group_label>
    <arm_group_label>Conventional Hepatitis B vaccine (20 μg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults between 20 and 50 years of age&#xD;
&#xD;
          2. Anti-HBs titers &lt; 10 mIU/mL&#xD;
&#xD;
          3. Subject is able to provide written informed consent by oneself or legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hepatitis B core antibodies positive patient&#xD;
&#xD;
          2. Patient has abnormal results in liver-function test&#xD;
&#xD;
          3. Patient has active microbial, viral, or fungal infections in need of systemic&#xD;
             treatment&#xD;
&#xD;
          4. Patient has history of serious heart disease (NYHA Functional Class III or IV heart&#xD;
             failure, myocardial infarction within 6 months, treatment required ventricular&#xD;
             tachyarrhythmias, or unstable angina etc.)&#xD;
&#xD;
          5. Patient has seizure disorder required anticonvulsants treatment&#xD;
&#xD;
          6. Serious chronic obstructive pulmonary disease patient accompanied hypoxemia&#xD;
&#xD;
          7. Uncontrollable diabetic patient&#xD;
&#xD;
          8. Uncontrollable hypertension patient&#xD;
&#xD;
          9. Patient with known history of HIV, HBV, or HCV infection&#xD;
&#xD;
         10. Subject had experience of participating other clinical study or clinical treatment&#xD;
             within 30 days before screening&#xD;
&#xD;
         11. Subject has hypersensitivity or anaphylactic reaction for HBV vaccine components&#xD;
&#xD;
         12. Patient being treated for prolonged immunosuppressive therapy (including steroids)&#xD;
&#xD;
         13. Hemodialysis patient&#xD;
&#xD;
         14. Subject has continuous drinking (&gt;21 units/week, 1 unit = 10g of pure alcohol) or&#xD;
             dependence on alcohol&#xD;
&#xD;
         15. Subject is pregnant or breastfeeding or intending to become pregnant during the study&#xD;
&#xD;
         16. Subject has any other significant findings unacceptable in this study under the&#xD;
             opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong Gyu Hwang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bundang CHA General Hospital</affiliation>
  </overall_official>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

